News
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...
Peach Twists on MSN21h
Living with Alopecia as a Black WomanHair has always been more than just a style—especially in the Black community, where our coils, curls, and protective styles ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback